🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,589 results for “Pharma” Clear

  1. OMP-59R5

    Mereo BioPharma Group plc

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  2. OMTX705-006 Phase 1b

    Lacuna Pharma Pty Ltd

    Advanced/Metastatic Pancreatic Adenocarcinoma

    phase 1 other active

    1 trial

  3. ONC206

    Jazz Pharmaceuticals Ireland Limited

    Diffuse Midline Glioma (DMG)

    phase 1 small molecule active

    1 trial

  4. ONC206

    Jazz Pharmaceuticals Ireland Limited

    Central Nervous System Neoplasms

    phase 1 small molecule active

    1 trial

  5. ONO-4578

    Ono Pharmaceutical Co.,

    Metastatic Pancreatic Cancer

    phase 1 small molecule completed

    1 trial

  6. OP-3136

    Olema Pharmaceuticals

    Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)

    phase 1 small molecule active

    1 trial

  7. ORX142 Tablets

    Centessa Pharmaceuticals plc

    Excessive Daytime Sleepiness

    phase 1 small molecule active

    1 trial

  8. ORX489 Tablets

    Centessa Pharmaceuticals plc

    Healthy Adult Male and Female Volunteers

    phase 1 small molecule active

    1 trial

  9. Obatoclax mesylate (GX15-070MS)

    Teva Pharma GmbH

    Hematological Malignancies

    phase 1 small molecule completed

    1 trial

  10. Olanzapine Extended Release

    Teva Pharma GmbH

    Schizophrenia, Schizoaffective Disorder

    phase 1 small molecule completed

    1 trial

  11. Olezarsen

    IONIS PHARMACEUTICALS INC

    Healthy Participants

    phase 1 small molecule completed

    1 trial

  12. Ologen Collagen Matrix

    AEON Biopharma

    Congenital Glaucoma

    phase 1 other active

    1 trial

  13. Olutasidenib Investigational Agent Administration

    RIGEL PHARMACEUTICALS INC

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  14. Omacetaxine

    Teva Pharma GmbH

    Hematologic Tumors

    phase 1 small molecule completed

    1 trial

  15. Omeprazole 40 MG

    LEXICON PHARMACEUTICALS, INC.

    Drug-drug Interaction

    phase 1 small molecule completed

    1 trial

  16. Ondansetron

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    2 trials

  17. Open label, Phase I study to assess and compare the pharmacokinetic parameters after multiple oral administration of stiripentol 1000 mg in renal impaired patients and matching controls with normal renal function

    Biocodex

    Patients with renal impairement

    phase 1 other active

    1 trial

  18. Open label, single-center, cross-over randomized, relative bioavailability study comparing a new pitolisant hydrochloride tablet formulation versus the marketed pitolisant (Wakix®) tablet formulation after single oral administrations in healthy subjects.

    Bioprojet Pharma

    narcolepsy with cataplexy, Narcolepsy

    phase 1 other active

    1 trial

  19. Open label, single-center, cross-over randomized, relative bioavailability study comparing a new pitolisant hydrochloride tablet formulation at 4 different strengths versus the marketed pitolisant (Wakix®) tablet formulation after single oral administrations in healthy subjects

    Bioprojet Pharma

    Narcolepsy, Narcolepsy with cataplexy

    phase 1 other active

    1 trial

  20. Open label, single-center, two-part pharmacokinetic study: Part I: Relative bioavailability study to compare the pharmacokinetics of BP1.4979 after administration of single oral doses of BP1.4979 as sustained release formulation and actual immediate release formulation, under fasting and fed conditions, in healthy subjects. Part II: Pharmacokinetics of BP1.4979 after a 14-day dosing period with b.i.d. administration of BP1.4979 as sustained release formulation in healthy subjects.

    Bioprojet Pharma

    Binge eating disorder

    phase 1 other active

    1 trial

  21. Open-label, non-randomised, single-dose, one sequence, two-period, cross-over study to investigate the effect of inhibition of P-glycoprotein and breast cancer resistance protein transporters by cyclosporine on the pharmacokinetics of CHF6001 in healthy volunteers.

    Chiesi Farmaceutici S.p.A

    Chronic obstructive pulmonary disease

    phase 1 other active

    1 trial

  22. Open-label, randomized, two-treatment, two-period, two-sequence, cross-over, single dose, bioequivalence study comparing ISOPRINOSINE® FORTE 100 mg/mL Syrup to ISOPRINOSINE® 500 mg tablets in healthy male and female subjects under fasting conditions.

    Lacuna Pharma Pty Ltd

    not applicable (submitted trial is a bioequivalence study)

    phase 1 other active

    1 trial

  23. Oral Fosmanogepix

    Basilea Pharmaceutica

    Healthy

    phase 1 small molecule completed

    1 trial

  24. Oxcarbazepine

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources